MedTrace Logo

Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies

NCT07004244 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-06-24

No results posted yet for this study

Summary

The goal of this study is to evaluate the safety and efficacy of mRNA vaccine for the KRAS mutation malignant tumors.

Conditions

  • Malignant Tumors

Interventions

BIOLOGICAL

KRAS-mutated mRNA vaccine

Cohort 1:From the initial dose, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose. Cohort 2:KRAS-mutated mRNA vaccine+ Toripalimab + pemetrexed + carboplatin as neo-adjuvant treatment followed by surgery

BIOLOGICAL

TORIPALIMAB

intravenous injection

DRUG

Pemetrexed+carboplatin

intravenous injection

Sponsors & Collaborators

  • West China Hospital

    collaborator OTHER

  • Sichuan University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-05
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07004244 on ClinicalTrials.gov